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Dampness and mold exposures in buildings are 
common, with estimates ranging from 18% 
to 50% of buildings (Gunnbjornsdottir et al. 
2006; Mudarri and Fisk 2007). A large num­
ber of studies in many geographical regions 
have found consistent associations between evi­
dent indoor dampness or mold and respiratory 
or allergic health effects in infants, children, 
and adults [Institute of Medicine (IOM) 2004; 
World Health Organization (WHO) Europe 
2009]. A review by the IOM (2004) reported 
documented associations, but not documented 
causal relationships, between indoor damp­
ness and upper respiratory tract symptoms, 
cough, wheeze, and asthma symptoms in sensi­
tized persons, but not for asthma development. 
A more recent review by WHO up to 2007 
expanded the observed associations to include 
asthma development, current asthma, dysp­
nea, and respiratory infections (WHO Europe 
2009). Associations were found in both atopic 
and nonatopic individuals. Other published 
reviews or opinion pieces on this topic are 
available (e.g., Bornehag et al. 2004; Douwes 
2005; Mudarri and Fisk 2007).
The consistent associations between evident 
dampness or mold and health may represent 
underlying causal relationships between fungal 
exposures and health. However, conventional 
quantitative measurements of fungi or other 
microbiologic exposures, such as counts of cul­
turable airborne fungi, have shown less consis­
tent associations with health effects than have 
qualitative assessments of visible dampness or 
water damage, visible mold, or mold odor. 
Thus, although a causal role for microbiologic 
exposures is plausible and likely, the evidence 
for this is still weak (Douwes and Pearce 2003). 
This is likely attributable in part to the lack of 
valid exposure assessment methods for the still 
unknown causal agents, microbial and pos­
sibly nonmicrobial, that increase with damp­
ness and directly cause adverse respiratory and 
  allergic effects.
Much additional epidemiologic research 
on qualitative and quantitative assessments 
of dampness and dampness­related agents has 
become available in the last few years. The 
present review combines findings of the IOM 
review of findings up to 2003 (IOM 2004) 
and a new assessment of later published stud­
ies. In this review we provide a) an updated, 
comprehensive review of available epidemio­
logic evidence on qualitative assessments 
of dampness or mold factors, and b) a new 
synthesis of evidence on quantitative meas­
ure  ments of microbiologic factors. Earlier 
work on this review (summarizing literature 
through 2007) was originally done to support 
the WHO Guidelines for Indoor Air Quality 
related to dampness and mold (2009).
Methods
The online database PubMed (National 
Library of Medicine 2010) was searched using 
three groups of keywords such as dampness, 
damp, “water damage,” moisture, humid­
ity, fungi, fungus, mold, mould, bacteria, or 
microorganisms, crossed with health, asthma, 
allergy, eczema, wheeze, cough, respiratory, 
“respiratory infection,” lung, skin, nasal, nose, 
“hypersensitivity pneumonitis,” alveolitis, 
bronchial, hypersensitivity, or inflammation 
and with building, house, home, residence, 
dwelling, office, school, or “day­care center.” 
A similar search was run in the ISI/Web 
of Knowledge database (Thomson Reuters 
2010). We identified additional publications 
from reference lists and personal databases. 
Some indoor exposures/conditions were not 
included, for example, humidity, mattress 
moisture, and dust mites.
Inclusion of a primary study required the 
following characteristics:
•	Publication	in	a	peer-reviewed	journal	by	
November 2009
•	Reporting	of	original	data	from	one	of	the	
following study designs: intervention (qua­
si­experimental intervention), prospective 
(prospective cohort), retrospective (retro­
spective cohort or nested case–control), or 
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oBjectives: Many studies have shown consistent associations between evident indoor dampness or 
mold and respiratory or allergic health effects, but causal links remain unclear. Findings on meas-
ured microbiologic factors have received little review. We conducted an updated, comprehensive 
review on these topics.
da t a s o u r c e s: We reviewed eligible peer-reviewed epidemiologic studies or quantitative meta-
analyses, up to late 2009, on dampness, mold, or other microbiologic agents and respiratory or 
allergic effects.
da t a e x t r a c t i o n: We evaluated evidence for causation or association between qualitative/ 
subjective assessments of dampness or mold (considered together) and specific health outcomes. 
We separately considered evidence for associations between specific quantitative measurements of 
microbiologic factors and each health outcome.
da t a synthesis: Evidence from epidemiologic studies and meta-analyses showed indoor dampness 
or mold to be associated consistently with increased asthma development and exacerbation, current 
and ever diagnosis of asthma, dyspnea, wheeze, cough, respiratory infections, bronchitis, allergic 
rhinitis, eczema, and upper respiratory tract symptoms. Associations were found in allergic and 
nonallergic individuals. Evidence strongly suggested causation of asthma exacerbation in children. 
Suggestive evidence was available for only a few specific measured microbiologic factors and was in 
part equivocal, suggesting both adverse and protective associations with health.
co n c l u s i o n s: Evident dampness or mold had consistent positive associations with multiple allergic 
and respiratory effects. Measured microbiologic agents in dust had limited suggestive associations, 
including both positive and negative associations for some agents. Thus, prevention and remedia-
tion of indoor dampness and mold are likely to reduce health risks, but current evidence does not 
support measuring specific indoor microbiologic factors to guide health-protective actions.
key w o r d s : allergy, asthma, dampness, fungi, indoor air, moisture, mold. Environ Health Perspect 
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cross­sectional (cross­sectional or prevalence 
case–control)
•	No	minimum	study	size,	but	if	exposure	
was characterized only at the building level, 
inclusion of > 10 buildings
•	Including	risk	factors	related	to	dampness	
or microbiologic organisms/components/
products, other than allergens (dust mites, 
cockroaches, mice)
•	Including	allergic	or	respiratory	health	effects
•	Providing	adequate	control,	in	study	design	
or analysis, of selection bias and confound­
ing from key variables: sex, smoking (active 
in adults, passive in children), and socio­
economic status (SES; control for SES not 
required if SES shown not to confound in 
study, if adjusted for race when race highly 
correlated with SES, if study conducted 
within specific occupational groups, or if 
study from Nordic countries or Holland).
We gave primary consideration to associa­
tions between specific health outcomes (e.g., 
wheeze) and one or more qualitative assess­
ments of indoor dampness or mold (e.g., vis­
ible dampness, visible mold, water damage, or 
mold odor), with the latter grouped for review. 
We refer to this set of factors collectively as evi­
dent dampness or mold, qualitatively assessed 
dampness or mold, or simply dampness or 
mold. Each study generally reported multi­
ple findings (for example, four findings from 
a study reporting estimates for associations 
between visible dampness and daytime wheeze, 
visible dampness and nighttime wheeze, mold 
odor and daytime wheeze, and mold odor 
and nighttime wheeze). Based on all currently 
available evidence, including studies reviewed 
in the IOM report, new studies included in 
this review, and findings from available quan­
titative meta­analyses, we drew conclusions 
about associations between specific health out­
comes and qualitatively assessed dampness or 
mold (excluding quantitative assessments of 
microbiologic factors). In “Results,” we gener­
ally refer to all ratio estimates of effect as odds 
ratios (ORs), although a few studies used other 
types of ratio estimates.
In this review we classified strength 
of evidence using the same categories as the 
IOM review on dampness and health (IOM 
2004) (box ES­1, p. 8): sufficient evidence 
of a causal relationship, sufficient evidence 
of an association, limited or suggestive evi­
dence of an association, and inadequate or 
insufficient evidence to determine whether 
an association exists. For each relationship 
considered, we classified the evidence using 
professional judgment on its persuasiveness, 
based on reported findings plus the strength, 
quality, diversity, and number of studies. 
Findings from quantitative meta­  analyses 
were also considered. We placed increasing 
weight in the review on studies of stronger 
design. The strongest epidemiologic evidence 
was considered to come from individually 
randomized controlled experimental/interven­
tion trials that added or removed risk factors. 
Studies considered next strongest were pro­
spective (cohort), followed by retrospective 
(cohort or nested case–control), observational 
studies. We considered cross­sectional obser­
va  tional studies (including prevalence case– 
control studies) to provide the weakest evidence 
included. A set of strongly designed human 
studies of different designs and in different 
populations, with findings generally consistent 
in direction and magnitude, especially if mag­
nitudes of effect were large or dose–response 
relations were found, was considered to provide 
the most persuasive overall evidence.
We drew separate conclusions, more pre­
liminary because evidence was sparse, about 
associations between specific health outcomes 
and specific quantitatively assessed micro­
biologic factors. For findings on associations 
between a specific outcome and a specific 
measured indoor microbiologic factor, our 
criteria for evidence suggestive of associations 
required at least 80% consistency of estimates 
either ≤ 1.0 or > 1.0 (with no minimum 
change from the null required) among at least 
five estimates available from three or more 
studies. This rough tally of findings above or 
below the null did not consider magnitude of 
effects, precision, statistical significance, study 
design, or age of subjects.
Results
IOM review. The IOM review of epidemio­
logic evidence to 2003 on dampness­related 
health effects found no demonstrated causal 
associations (IOM 2004). Sufficient evidence 
of association was reported for four outcomes 
(upper respiratory tract symptoms, cough, 
wheeze, and asthma symptoms in sensitized 
persons, i.e., asthma exacerbation) for the 
two kinds of risk factor considered: exposure 
to damp indoor environments and presence 
of molds or other agents in damp indoor 
environ  ments. Sufficient evidence of asso­
ciation was also reported between hypersen­
sitivity pneumonitis in susceptible persons 
and mold or other agents in damp environ­
ments. The 45 studies included in the IOM 
review are summarized in Supplemental 
Material, Tables A1.1–A1.6 (doi:10.1289/
ehp.1002410). Table 1 shows the numbers of 
studies included in the IOM review, by study 
design, for each type of health outcome.
New primary research. Our literature 
search identified 354 articles published by 
late 2009 that were not included in the IOM 
review. Table 1 categorizes 103 studies that 
met the inclusion criteria. Supplemental 
Material, Tables A2.1–A2.16 (doi:10.1289/
ehp.1002410) summarize results of these 
studies by 16 health outcomes. Estimated 
strength of association was usually reported 
as ORs and 95% confidence intervals (CIs), 
but occasionally was reported as other ratio 
estimates such as relative risks (RRs) or inci­
dence rate ratios (IRRs) or as linear regression 
coefficients or proportions.
Considering all current evidence, most 
published findings involved qualitative assess­
ments of dampness or mold, including visible 
water damage, visible moisture, dampness, 
leaks, flooding, visible condensation on win­
dows, visible mold or mildew, and moldy or 
musty odor. Fewer findings were available on 
quantitatively measured microbiologic factors, 
including specific or total culturable fungi or 
bacteria; microscopically enumerated, noncul­
tured fungi or bacteria; ergosterol (a structural 
component of fungi, used as a marker for total 
fungal biomass); extracellular polysaccharides 
(produced by fungi and used as a marker for 
specific fungal groups); (1→3)­β­d­glucans 
(a cell wall compound with immunomodu­
lating properties found in fungi but also in 
some bacteria and pollens); endotoxin or 
lipopolysaccharide (a cell­wall compound of 
Gram­negative bacteria with proinflamma­
tory properties, associated with dampness but 
also with many other sources); and markers of 
endotoxin such as 3 hydroxyl fatty acids. 
Meta-analyses. Three available quantitative 
meta­analyses combined multiple qualitative 
dampness or mold factors into a single set of 
dampness­related risk factors. Findings, sum­
marized in Table 2, are described for specific 
outcomes below. Two meta­analyses using 
the same methods estimated summary ORs 
and 95% CIs for associations of dampness or 
mold in residences with respiratory effects: 
upper respiratory tract symptoms, cough, 
wheeze, asthma development, current asthma, 
and ever­diagnosed asthma (Fisk et al. 2007), 
and respiratory infections and bronchitis (Fisk 
et al. 2010). Antova et al. (2008) estimated 
summary ORs for dampness­related factors 
and ever­diagnosed asthma, bronchitis, allergic 
sensitization, hay fever, cough, and wheeze.
Results for qualitative dampness or mold. 
We considered no health outcomes to have 
sufficient evidence to document a causal rela­
tionship with indoor dampness or mold.  
We considered four health outcomes to 
have sufficient evidence for association with 
indoor dampness or mold that were already so 
classified in the IOM review: asthma exacer­
bation, cough, wheeze, and upper respiratory 
tract symptoms (Table 3).
For asthma exacerbation and dampness or 
mold, we consider current evidence sufficient 
to document association and strongly sugges­
tive of causality. Among 31 currently available 
studies [see Supplemental Material, Tables A1.2 
and A2.2 (doi:10.1289/ehp.1002410)], quali­
tative dampness­related factors were consis­
tently associated with asthma exacerbation, 
with ORs consistently exceeding 1.0 in both Mendell et al.
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adults [100% of findings in retrospective stud­
ies (ORs from 1.7 to 2.6) and 100% of find­
ings in cross­sectional studies (ORs from 1.02 
to 4.2)] and in children [100% of findings in 
intervention studies (protective associations, 
not reported as ORs), 100% of findings in 
prospective studies (ORs from 3.8 to 7.6), 
100% of findings in retrospective studies (ORs 
from 1.5 to 4.9), and 95% of findings in cross­
sectional studies (ORs from 1.0 to 7.6)]. Most 
notably, Kercsmar et al. (2006) conducted a 
controlled experimental intervention study on 
asthma exacerbation in houses of highly symp­
tomatic asthmatic children. Comprehensive 
removal of dampness sources and visible mold 
caused dramatic reductions in asthma exacer­
bations. Acute care visits at 6–12 months after 
intervention were 90% fewer in those remedi­
ated versus controls (p = 0.003). This study 
(although of necessity unblinded), because of 
the implausibility of noncausal explanations 
for the findings and in conjunction with other 
available studies, strongly suggests a causal asso­
ciation between indoor dampness or mold and 
exacerbations in children with asthma.
For cough, most studies found positive 
associations with dampness or mold. In adults, 
94% of ORs in cross­sectional studies exceeded 
1.0 (range, 0.8–4.0). In children, 85% of ORs 
in prospective or retrospective studies exceeded 
1.0 (range, 0.5–2.1), and 94% of cross­
  sectional ORs exceeded 1.0 (range, 0.2–5.7).
For wheeze, most studies found posi­
tive associations with dampness or mold. In 
adults, 100% of retrospective ORs exceeded 
1.0 (range, 1.5–2.8), and 91% of cross­ 
sectional ORs exceeded 1.0 (range, 0.4–5.8). 
In children, 95% of prospective or retrospec­
tive ORs exceeded 1.0 (range, 0.7–6.2), and 
92% of cross­sectional ORs exceeded 1.0 
(range, 0.5–8.7).
For upper respiratory tract symptoms, 
most studies found positive associations with 
dampness or mold. In adults, 81% of cross­
sectional ORs exceeded 1.0 (range, 0.4–4.4). 
In children, 88% of prospective or retrospec­
tive ORs exceeded 1.0 (range, 1.0–1.8), and 
95% of cross­sectional ORs exceeded 1.0 
(range, 0.4–5.9).
We classified eight health outcomes as 
having sufficient evidence for association with 
indoor dampness or mold that were not so 
classified or not evaluated in the IOM review: 
asthma development, current asthma, asthma 
ever, dyspnea, respiratory infections, bronchi­
tis, allergic rhinitis, and eczema (Table 3).
Asthma development is a health out­
come of special public health importance. 
Five studies included in the IOM report [of 
the eight listed there for asthma develop­
ment; see Supplemental Material, Table A1.1 
(doi:10.1289/ehp.1002410)] explicitly exam­
ined associations between dampness or mold 
and asthma development (Jaakkola et al. 
2002; Nafstad et al. 1998; Oie et al. 1999; 
Thorn et al. 2001; Yang et al. 1998). Eight 
new studies were identified (Supplemental 
Material, Table A2.1) (Cox­Ganser et al. 2009; 
Gunnbjornsdottir et al. 2006; Hyvarinen 
et al. 2006; Iossifova et al. 2009; Jaakkola 
et al. 2005; Matheson et al. 2005; Park 
et al. 2008; Pekkanen et al. 2007). Among 
all currently available studies (five studies in 
Supplemental Material, Table A1.1; all studies 
in Supplemental Material, Table A2.1), 78% 
of findings exceeded 1.0. In retrospective case–
control studies of adults, 60% of ORs exceeded 
1.0 (range, 0.8–2.2). Among children, 80% of 
prospective or retrospective/case–control ORs 
exceeded 1.0 (range, 0.6 to 4.1). The three 
studies in infants (Iossifova et al. 2009; Nafstad 
et al. 1998; Oie et al. 1999) reported ORs all 
exceeding 1.0 (range, 1.7–7.1); however, as 
asthma cannot be reliably assessed in infants, 
these findings should be interpreted with cau­
tion. Infant studies were excluded from the 
Table 1. Total numbers of published studies on health effects: those cited by the IOM review (IOM 2004) 
and those identified later and included in this review, plus summarya of findings only for qualitativeb 
assessments of dampness or mold.
Health outcome category Study design
Total number of 
studies
Summary of qualitative assessments 
of dampness or moldb
Proportion of total estimates 
showing any positive 
association with D/Md
IOM 
review New OR rangec
Asthma development Prospective 2 4 0.65–7.08 7/9
Retrospective 6 2 0.63–4.12 29/38
Cross-sectional 0 3 1.6–2.2 2/2
Asthma symptoms in 
asthmatic people 
(exacerbation)
Intervention 0 3 No ORs 22/22
Prospective 0 1 3.8–7.6 2/2
Retrospective 5 0 1.5–4.9 7/7
Cross-sectional 18 4 1.0–7.6 45/47
Ever-diagnosed asthma Prospective — 2 1.2–1.3 2/2
Cross-sectional — 18 0.6–2.6 31/33
Current asthma Prospective — 1 No qual No qual
Cross-sectional — 25 0.3–13.0 60/64
Dyspnea Intervention 0 1 No ORs 2/2
Cross-sectional 4 11 0.4–9.4 56/67
Wheeze Intervention 0 1 No ORs 7/8
Prospective 0 12 0.68–6.17 35/37
Retrospective 1 1 1.5–2.8 9/9
Cross-sectional 19 41 0.44–8.67 151/164
Bronchitis Prospective — 1 0.7–3.8 4/5
Cross-sectional — 11 1.2–2.4 19/19
Altered lung function Intervention — 2 No ORs 6/6
Prospective — 2 No ORs 7/13
Retrospective — 1 No ORs 4/8
Cross-sectional — 6 No ORs 8/9
Cough Prospective 0 2 0.54–2.14 7/9
Retrospective 1 0 1.18–1.90 4/4
Cross-sectional 20 26 0.21–5.74 140/147
Respiratory infections 
and otitis media
Prospective — 5 0.45–5.1 14/24
Cross-sectional — 13 0.48–3.14 30/37
Common cold Prospective — 1 0.6–1.8 4/9
Cross-sectional — 5 0.98–1.7 13/14
Eczema Prospective — 2 1.2–2.9 3/3
Cross-sectional — 4 0.3–1.9 13/15
Allergy/atopy (excluding 
allergic rhinitis and eczema)
Prospective — 7 0.6–2.4 9/12
Cross-sectional — 15 1.1–1.9 15/19e
Allergic rhinitis Prospective — 2 1.2–3.2 5/5
Cross-sectional — 3 0.7–3.5 7/8
Upper respiratory tract 
symptoms (including 
allergic rhinitis)
Intervention 0 1 No ORs 5/6
Prospective 0 5 1.03–3.2 11/11
Retrospective 0 1 1.0–1.3 1/2
Cross-sectional 14 20 0.37–5.92 107/122
Other respiratory Prospective — 5 1.03–1.06 4/4
Cross-sectional — 13 0.45–2.4 11/14
Total studies 45f 103f
Abbreviations: —, outcome not included in review; D/M, dampness or mold; no qual, no qualitative exposure assess-
ments in article. 
aFor details regarding the studies in this table, see Supplemental Material, Tables A1.1-A1.6 and A2.1-A2.6 (doi:10.1289/
ehp.1002410). bFindings for quantified microbiologic factors omitted. cIncludes all reported ratio estimates of effect: ORs, 
RRs, IRRs. dProportion of findings with ORs, RRs, or IRRS > 1.0 (or < 1.0 for removal of D/M) or nonratio estimates, such 
as linear coefficients, greater/less than 0 or 1 as appropriate. eAlthough all reported ORs/RRs/IRRs exceeded 1.0, other 
types of estimates were not consistent. fTotals are less than the sum of the numbers above, as each study may report 
multiple findings.Health effects of dampness and mold
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meta­analysis of Fisk et al. (2007), which 
reported a summary OR (95% CI) of 1.3 
(0.9–2.1) for asthma development and damp­
ness factors. One of the strongest reported 
studies, by Pekkanen et al. (2007), showed 
in an incident case–control study of asthma 
cases that dampness or mold in the main living 
area of houses was related in a dose–response 
fashion to asthma development in infants and 
children. Multivariate­adjusted ORs (95% 
CIs) for asthma incidence, for baseline and 
two increasing levels of maximum severity of 
moisture damage (assessed by civil engineers), 
were 1.0, 2.8 (1.4–5.4), and 4.0 (1.6–10.2). 
This well­designed study provides the strongest 
evidence (e.g., incident case–control, large and 
statistically significant effects, dose–response 
relation, unbiased exposure assessment), within 
a body of generally consistent other findings, 
that dampness­related exposures may cause 
asthma development in infants and children.
For dyspnea, considered in the IOM 
report to have limited or suggestive evidence 
of association with dampness, the number 
of available studies for adults and children 
has increased from 4 to 16, all cross­sectional 
except 1 controlled intervention study. The 
intervention study found significant improve­
ments in perceived breathing after mold 
removal, fungicide application, and ventilation 
increase (Burr et al. 2007). Among the 14 
other available studies of dampness or mold 
[Supplemental Material, Tables A1.3 and 
A2.5 (doi:10.1289/ehp.1002410)], meas  ures 
of association for dampness or mold with dys­
pnea were predominantly (84%) > 1.0, with 
ORs ranging from 0.7 to 9.4 in adults and 
from 0.4 to 2.3 in children.
We included findings on current asthma 
when defined as either asthma diagnosis in 
prior 12 months, asthma diagnosis ever plus 
asthmatic symptoms in prior 12 months, or 
recent prescription of asthma medication. 
Current asthma, not specifically evaluated in 
the IOM review, was consistently associated 
in available studies [Supplemental Material, 
Table A2.4 (doi:10.1289/ehp.1002410)] with 
dampness or mold. In these cross­sectional 
studies of adults, children, or both, almost all 
ORs (94%) exceeded 1.0 (ranging from 0.3 
to 13.0). Fisk et al. (2007) reported, as a sum­
mary effect estimate, an OR (95% CI) of 1.6 
(1.3–1.9) for current asthma and qualitative 
dampness factors.
Ever­diagnosis with asthma [Supplemental 
Material,  Table  A2.3  (doi:10.1289/
ehp.1002410)] was associated consistently 
with dampness or mold (91% of ORs; range, 
0.6–2.6) in both adults and children. Most 
studies were cross­sectional and in children. 
All studies in adults and the single prospective 
study in children found completely consis­
tent positive associations. Both available meta­
analyses found increased summary ORs for 
ever­asthma diagnosis and residential damp­
ness or mold, with ORs (95% CIs) of 1.37 
(1.23–1.53) for children and adults in Fisk 
et al. (2007) and 1.35 (1.20–1.51) for children 
in Antova et al. (2008).
Studies on respiratory infections showed 
consistent associations between dampness or 
mold and respiratory infections [Supplemental 
Material, Table A2.11 (doi:10.1289/ehp. 
1002410)], including common colds, and 
Table 3. Level of confidence for associations between indoor dampness or dampness-related agentsa and health outcomes, based on epidemiologic evidence.b
Updated conclusiona Outcome Additional evidencec Prior IOM conclusion
Sufficient evidence of a causal relationship (None) (None) (None)
Sufficient evidence of association Asthma exacerbation  More studies of strong design (strongly 
suggestive of causation)
Sufficient evidence of association 
Coughd Many new studies, some of strong design Sufficient evidence of association
Wheezed Many new studies, many of strong design Sufficient evidence of association 
Upper respiratory tract symptomsd Many new studies, some of strong design Sufficient evidence of association
Asthma developmente More studies of strong design Limited or suggestive evidence of association
Dyspneae More studies Limited or suggestive evidence of association
Current asthmad,e Initial evaluation Not evaluated
Ever-diagnosed asthmad,e Initial evaluation Not evaluated
Respiratory infectionse Initial evaluation Not evaluated
Bronchitisd,e Initial evaluation Not evaluated
Allergic rhinitisd,e Initial evaluation Not evaluated
Eczemad,e Initial evaluation Not evaluated
Limited or suggestive evidence of association Common colde Initial evaluation Not evaluated
Allergy/atopyd,e Initial evaluation Not evaluated
Inadequate or insufficient evidence to 
determine whether an association exists
Altered lung function Initial evaluation Not evaluated
Hypersensitivity pneumonitis (None) (Association based on clinical evidence)
aBased on evidence of visible water damage, visible mold, mold odor, or similar related factors. bAssociation between hypersensitivity pneumonitis in susceptible individuals and the 
presence of mold or other agents is documented by clinical evidence (IOM 2004). cStudies of stronger design include experimental, cohort, or case–control designs. dStatistically sig-
nificant elevation of risk identified in a quantitative meta-analysis. eConclusion changed from IOM conclusion.
Table 2. Summary estimates from three meta-analyses on residential D/M and health.
Subject 
groups
OR (95% CI)
Outcome Fisk et al. 2007a Fisk et al. 2010a Antova et al. 2008b
Upper respiratory tract symptoms All 1.70 (1.44–2.00)
Cough All 1.67 (1.49–1.86)
Adults 1.52 (1.18–1.96) 1.30 (1.22–1.39)c
Children 1.75 (1.56–1.96) 1.50 (1.31–1.73)d
Wheeze All 1.50 (1.38–1.64)
Adults 1.39 (1.04–1.85) 1.43 (1.36–1.49)e
Children 1.53 (1.39–1.68) 1.49 (1.28–1.74)f
Current asthma All 1.56 (1.30–1.86)
Ever-diagnosed asthma All 1.37 (1.23–1.53)
Children 1.35 (1.20–1.51)
Asthma development All 1.34 (0.86–2.10)
Bronchitis All 1.45 (1.32–1.59)
Children 1.38 (1.28–1.47)
Respiratory infections All 1.44 (1.31–1.59)
Adults 1.49 (1.14–1.95)
Children 1.48 (1.33–1.65)
Respiratory infectionsg All 1.50 (1.32–1.70)
Sensitivity to inhaled antigens Children 1.33 (1.23–1.44)
Hay fever Children 1.35 (1.18–1.53)
aBased on all eligible published studies at the time, ranging from 4 to 22 studies for each outcome; all risk factors of vis-
ible mold, visible water damage, mold odor, and various combinations of these were included together. bBased on a total 
of 12 studies in 12 countries, including over 57,000 children: 10 studies of any visible mold, 1 study of any visible mold in 
last 12 months, and 1 study of any visible mold in child’s bedroom. cNocturnal dry cough. dMorning cough. eWheeze in 
the last 12 months. fWoken by wheeze. gIncluding lower respiratory infections, tonsillitis, sinusitis, otitis, and pharyngitis, 
but excluding nonspecific upper respiratory infections.Mendell et al.
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with or without inclusion of otitis media. 
One cross­sectional study in adults found an 
elevated OR (3.1); two prospective studies 
of children found consistently elevated ORs 
(range, 1.34–5.10); and five cross­sectional 
studies in children found mostly (70%) 
elevated ORs (range, 0.65–1.85). The few 
findings on otitis media, in three studies in 
children, included ORs ranging from 1.0 to 
1.37 for dampness or mold. The meta­anal­
ysis by Fisk et al. (2010) reported summary 
ORs and 95% CIs for various categories of 
respiratory infections (Table 2): for respiratory 
infections overall, in adults, and in children: 
1.44 (1.31–1.59), 1.49 (1.14–1.95), and 1.48 
(1.33–1.65), respectively, and for respiratory 
infections excluding nonspecific upper respira­
tory infections: 1.50 (1.32–1.70).
Dampness or mold was associated consis­
tently with bronchitis [Supplemental Material, 
Table A2.7 (doi:10.1289/ehp.1002410)], with 
96% of ORs > 1.0. Most studies were in chil­
dren; the two prospective studies in children 
found generally increased ORs up to 3.8. Both 
available meta­analyses found positive associa­
tions between bronchitis and residential damp­
ness or mold, with ORs (95% CIs) of 1.45 
(1.32–1.59) for children and adults in Fisk 
et al. (2010)  and 1.38 (1.38–1.47) for children 
in Antova et al. (2008).
Dampness or mold was associated consis­
tently with allergic rhinitis (92% of findings, 
all in children), with ORs ranging from 0.7 
to 3.5 [Supplemental Material, Table A2.14 
(doi:10.1289/ehp.1002410)]. We included 
only allergic rhinitis outcomes defined as 
either medically diagnosed allergic rhinitis or 
the combination of rhinitis symptoms with 
documented atopy. The strongest single study 
(prospective) found dose–response increases in 
allergic rhinitis associated with visible mold, 
with ORs to 3.2 (Biagini et al. 2006).
Dampness or mold was associated consis­
tently with eczema [Supplemental Material, 
Table A2.12 (doi:10.1289/ehp.1002410)], 
with 89% of ORs > 1.0 (range 0.2 to 2.9). 
The strongest study, a prospective study in 
children, found consistently increased ORs up 
to 2.9 for prenatal mold exposure to infants 
with no parental atopic history.
Other outcomes evaluated here but not 
in the prior IOM report include common 
cold, allergy/atopy, and altered lung func­
tion (Table 1). Common cold [Supplemental 
Material, Table A2.11 (doi:10.1289/
ehp.1002410)] was positively associated with 
dampness or mold in 71% of reported find­
ings. However, the methodologically strongest 
single study, a prospective study in children, 
found only 4 of 9 estimates elevated, with 
ORs ranging from 0.6 to 1.8. Therefore, we 
consider this association only suggestive.
Increase in allergy/atopy (excluding 
allergic rhinitis and eczema) [Supplemental 
Material, Table A2.13 (doi:10.1289/
ehp.1002410)] in association with dampness 
or mold was found in 77% of reported assess­
ments in the available studies; ORs ranged 
from 0.6 to 2.4. Findings in the strongest 
studies, two prospective studies in children, 
were overall somewhat inconsistent, as were 
the other studies. This association is made 
more plausible by the increased summary ORs 
in the meta­analysis by Antova et al. (2008) 
for sensitivity to inhaled antigens and for hay 
fever, as well as by the consistent association 
found in this review between dampness or 
mold and both allergic rhinitis and eczema. 
However, the overall evidence linking allergy/
atopy and dampness or mold was inconsis­
tent enough that we currently consider it only 
(strongly) suggestive.
The evidence associating altered lung func­
tion with dampness or mold [Supplemental 
Material, Table A2.8 (doi:10.1289/ehp. 
1002410)] was considered too inconsistent 
to draw conclusions. No eligible epidemio­
logic studies were found on hypersensitivity 
pneumonitis and dampness or mold (but see 
“Discussion” regarding overall evidence).
Results for measured microbiologic fac-
tors. Findings on health risks associated with 
quantitatively assessed microbiologic factors 
were sparse across specific health outcomes 
and 53 specific types of microbial measure­
ments. Suggestive associations (as defined in 
“Methods” for conclusions about quantitatively 
assessed microbiologic factors: requiring at least 
80% consistency of estimates either ≤ 1.0 or 
> 1.0, among at least five estimates available 
from three or more studies) were not seen for 
measurements in air but were apparent for 
some measurements in dust (Table 4). Higher 
concentrations of ergosterol in dust were 
associated with increases in current asthma. 
Higher concentrations of endotoxin in dust 
were associated with increases in wheeze. For 
(1→3)­β­d­glucan in dust, although medium 
concentrations were associated with increases in 
wheeze, the highest concentrations were associ­
ated with decreases in wheeze. We consider 
these associations with quantitative microbio­
logic assessments to be only suggestive. Other 
microbial measurements used in reviewed stud­
ies [listed in Supplemental Material, Table A3.1 
(doi:10.1289/ehp.1002410)] had inadequate 
or insufficient evidence to determine whether 
associations with specific health effects exist.
Discussion
Epidemiologic evidence from primary stud­
ies and quantitative meta­analyses shows evi­
dent indoor dampness or mold to be associated 
consistently with a wide range of respiratory 
or allergic health effects, including asthma 
develop  ment and exacerbation, current and 
ever diagnosis of asthma, dyspnea, wheeze, 
cough, respiratory infections, bronchitis, aller­
gic rhinitis, eczema, and upper respiratory tract 
symptoms. In addition to the consistently posi­
tive associations across many study designs, 
populations, ages, and health outcomes, dose–
response relations with observed dampness and 
mold were often reported (e.g., Biagini et al. 
2006; Cummings et al. 2008; Park et al. 2004; 
Table 4. Measured indoor microbiologic factors with suggestive positive or negative associationsa with specific respiratory or allergic health effects in building 
occupants.b
Measured microbiologic factors
Specific health 
outcomes
Findings with 
suggestive positive 
associations
Findings with 
suggestive negative 
associations
No. of 
studies
Range of 
ORs References
Ergosterol in dust, higher levels Current asthma 5 of 6 (83%) 3 0.92–4-fold Dharmage et al. 2001; Matheson et al. 2005; 
Park et al. 2008
Endotoxin in dust, higher levels Wheeze 20 of 25 (80%) 14 0.67–2.8 Iossifova et al. 2007, 2009; Park et al. 2001, 
2006; Zhao et al. 2008; Schram-Bijkerk et al. 
2005; Bolte et al. 2003; Campo et al. 2006; 
Douwes et al. 2006; Gehring et al. 2008; 
Gillespie et al. 2006; Litonjua et al. 2002; 
Perzanowski et al. 2006
(1→3)-β-d-glucans in dust, medium levels Wheeze 7 of 8 (88%) 3 0.89–6.05 Douwes et al. 2006; Iossifova et al. 2007, 2009
(1→3)-β-d-glucans in dust, highest levels Wheeze 10 of 11 (91%) 4 0–1.25 Douwes et al. 2006; Iossifova et al. 2007, 
2009; Schram-Bijkerk et al. 2005
aA suggestive association required, among reported findings on associations between a specific measured indoor microbiologic factor and a specific respiratory or allergic health 
outcome, at least 80% consistency of estimates either ≤ 1.0 or > 1.0, among at least five estimates available from three or more studies. This assessment did not consider magnitude of 
effects, precision, statistical significance, study design, or age of subjects. bMeasured microbiologic factors with inadequate or insufficient evidence to determine whether an associa-
tion exists with any specific health outcome are listed in Supplemental Material, Table A3.1 (doi:10.1289/ehp.1002410).Health effects of dampness and mold
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Pekkanen et al. 2007). Although available epi­
demiologic evidence does not yet establish that 
indoor dampness or mold causes human health 
effects, findings from one strong epidemio­
logic intervention study (Kercsmar et al. 2006), 
in conjunction with other available studies, 
strongly suggest causation of asthma exacerba­
tion in children by dampness or mold. Several 
studies provide evidence for temporal asso­
ciation of dampness/mold and health effects 
by demonstrating increased incidence density 
of new asthma diagnosis among occupants 
of water­damaged buildings compared with   
periods before water damage (Cox­Ganser et al. 
2005; Laney et al. 2009).
It is well accepted that hypersensitiv­
ity pneumonitis (HP), a granulomatous, cell­ 
mediated lung inflammation, is caused by inha­
lation of antigens from microorganisms or other 
sources, although causal exposures often can­
not be determined (Fink et al. 2005). Current 
knowledge is based on outbreak investigations 
and limited epidemiology, mostly in indus­
trial and agricultural settings, but also in office 
buildings (Cox­Ganser et al. 2005; Kreiss 1989; 
Park et al. 2004) and, in both adults and chil­
dren, in homes (Venkatesh and Wild 2005). 
One specific dampness­related mold exposure 
(Trichosporon cutaneum) is documented to cause 
HP in homes (Ando et al. 1995). [For more 
on HP, see Supplemental Material, Text A4.1 
(doi:10.1289/ehp.1002410).]
Few studies included objective, replicable 
assessments of dampness. Both Karvonen et al. 
(2009) and Park et al. (2004), using scales 
combining area of water damage or area of 
water stains with subjective assessments, found 
exposure–response relations with multiple 
health outcomes. Williamson et al. (1997), 
using a scale based only on moisture meter 
readings from walls, also found positive 
adjusted associations, for example, ORs (95% 
CIs) for asthma and any dampness of 3.03 
(1.65–5.57), exceeding ORs for subjective 
inspector­determined visible mold. Williamson 
et al. (1997) also found positive correlations 
between total moisture meter dampness score 
and both asthma severity (p = 0.0006) and 
predicted FEV1 (forced expiratory volume in 
1 sec) (p = 0.006). One potential advantage of 
quantitative dampness measurements as indi­
cators of exposure, relative to specific quan­
titative microbial measurements, is that they 
can be proxies for various dampness­related 
causal agents, whether microbial or chemical. 
Quantifying visible mold may also prove use­
ful; however, Dales et al. (2010) found no sig­
nificant relationship between measured area of 
visible mold and respiratory health outcomes.
Although evidence is limited that links any 
quantitative microbial measurements to specific 
health effects, in this review we have identified 
some preliminary associations (Table 4), all 
for measurements in dust: increased ergosterol 
with increased current asthma; increased endo­
toxin with increased wheeze; and for (1→3)­
β­d­glucans, medium concentrations with 
increased wheeze but the highest concentra­
tions with decreased wheeze. We consider these 
associations to be only suggestive, because of 
the limited number of studies, the limited fac­
tors considered in summarizing them, and the 
demonstrated complexity of some of these rela­
tionships, such as for endotoxin and (1→3)­β­
d­glucans, each associated in multiple studies 
with both adverse and protective associations 
(Douwes et al. 2004, 2006).
Current findings thus cannot define causal 
microbiologic exposures or dose–response 
relations sufficiently to define safe levels of 
exposure to dampness­related agents. At pres­
ent, subjectively assessed dampness or mold 
has the most consistently documented asso­
ciations with respiratory and allergic disease. 
Quantifying dampness objectively has shown 
promise (Karvonen et al. 2009; Park et al. 
2004; Williamson et al. 1997), but findings 
are few. For quantifying microbiologic factors, 
concentrations of culturable airborne organ­
isms have fared poorly in empirical health 
research. Some assessments in dust, such as 
ergosterol as an indicator of total biomass of 
fungi, are more promising; others, such as 
endotoxin and glucans, have relationships 
with health too complex for simple interpreta­
tion. Polymerase chain reaction (PCR) assays 
for specific fungi in dust also have promise, 
but no studies using PCR met inclusion 
criteria for this review, and a standard scale 
now used to group PCR findings across fungi 
seems premature (e.g., Vesper et al. 2007). 
[For details, see Supplemental Material, 
Text A4.2 (doi:10.1289/ehp.1002410).]
Difficulties in finding clear relationships 
with measured microbiologic exposures may 
be attributable to measurement errors in expo­
sure assessment, including measurement of 
noncausal factors; to effects that change with 
intensity and duration of exposure or age at 
exposure; or to interaction effects occurring 
with multiple exposures. Endotoxin, tradi­
tionally associated with non­dampness­related 
exposures such as farm animals and pets and 
with potential protection against atopy, has 
now been shown to be associated in water­ 
damaged office buildings with observed damp­
ness, fungal spores, and increased building­
related asthmatic symptoms (Park et al. 2006; 
Rao et al. 2005). Adverse effects from endo­
toxin may be increased by other dampness­
associated agents and vice versa (Park et al. 
2006). In addition, moisture in buildings can 
increase nonbiologic emissions not measured 
in most dampness research, including form­
aldehyde [associated with increased asthma 
(McGwin et al. 2009; Mendell 2007)] from 
composite wood products (Matthews et al. 
1986) and 2­ethyl­1­hexanol from moisture­
related degradation of plasticizer in vinyl floor­
ing (Norbäck et al. 2000).
Based on available evidence, dampness and 
mold may have enormous health and social 
costs worldwide. A northern European study 
found an 18% prevalence of indoor damp­
ness (Gunnbjornsdottir et al. 2006). The 
IOM review (IOM 2004), using European 
and North American data, estimated that at 
least 20% of buildings had problems with 
dampness. Mudarri and Fisk (2007) estimated 
a 50% prevalence of dampness or fungi in 
U.S. houses. Fisk et al. (2007) concluded that 
“building dampness and mold are associated 
with approximately 30–50% increases in a 
variety of respiratory and asthma­related health 
outcomes.” Mudarri and Fisk (2007) esti­
mated that 21% of current U.S. asthma cases 
were potentially attributable to dampness and 
mold in housing, for an annual national cost 
of $3.5 billion. Fisk et al. (2010) estimated 
that residential dampness or mold is associated 
with 8–20% of U.S. respiratory infections.
With regard to practical implications of 
these findings, we did not evaluate health 
bene  fits of specific strategies for remediation of 
dampness or mold. However, a recent expert 
review has concluded that the intervention of 
“combined elimination of moisture intrusion 
and leaks and removal of moldy items” had 
sufficient evidence of effectiveness for reducing 
respiratory symptoms from asthma and aller­
gies and was ready for widespread implemen­
tation (Krieger et al. 2010).
Limitations. Much of the epidemiology 
on dampness, mold, and health has used sub­
jective reports for assessing exposure or health 
and thus has potential for reporting bias. 
Two reviews have considered whether biased 
subjective response by building occupants in 
dampness studies might have positively biased 
findings. On the basis of comparison of results 
in six studies from occupant reports versus 
inspector­reported dampness and clinically 
determined illness, Fisk et al. (2007) con­
cluded that observed associations of respiratory 
health effects with dampness­related exposures 
were unlikely to be explained by over  reporting. 
Bornehag et al. (2001) reported that findings 
of studies with independent assessment of 
both dampness and health effects were similar 
to findings of studies with more subjective 
information sources. Additionally, avoidance 
behavior (prior exposure reductions by persons 
with asthma) may be a source of past exposure 
misclassification with assessment of only cur­
rent or recent exposure. However, this is not a 
concern in prospective or intervention studies, 
which have generally confirmed dampness/
health associations.
Quantitative measures of exposure used 
in the reviewed studies also have important 
limitations. Measured airborne concentrations 
of culturable microorganisms have substantial Mendell et al.
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errors, for example, from short­term estimation 
of airborne concentrations with large and rapid 
variations over time; from differential abilities 
of organisms to grow on specific culture media; 
and from nondetection by culture assays of 
most bioactive microbial materials, whether 
intact spores or fragments. Most important, 
culture­based or non­culture­based microbial 
measurements used in many studies may not 
target actual causal factors. All these reasons 
may explain the lack of consistent associations 
between reported microbial measurements and 
health. And as with glucans or endo  toxins, 
even prior demonstration in many studies 
that a substance causes inflammation does not 
implicate it as consistently harmful, because 
both glucans and endotoxins have also demon­
strated health­protective associations (Douwes 
et al. 2006; Iossifova et al. 2007). However, 
subjectively assessed dampness or mold has not 
shown protective associations, even in infants.
Finally, definitions of respiratory health 
effects are not standardized, potentially caus­
ing bias. In population studies, asthma is usu­
ally defined by self­reported (or parentally 
reported) asthma symptoms. Self­reports of 
doctor­diagnosed asthma are also often used. 
An alternative approach to questionnaires has 
been to use more objective measures, either 
alone or in combination with questionnaires. 
As with measures of home dampness or fun­
gal exposures, differences in asthma definition 
are likely to result in differences in estimates 
of RRs. In addition, as mentioned above, sev­
eral studies (Nafstad et al. 1998; Oie et al. 
1999) focused on infants at an age where the 
diagnosis of asthma is uncertain. Most of 
these potential sources of bias are expected to 
underestimate any true association between 
indoor dampness and health effects.
The restricted scope of this review led to 
further limitations. The method of evaluating 
published evidence was largely nonquantitative. 
Results of available quantitative meta­analyses, 
however, are consistent with qualitative sum­
maries. Publication bias in this review is likely 
to have inflated associations of risk factors with 
health effects. A formal application of available 
statistical methods for assessing presence of this 
bias was not feasible for this broad review. A 
search for unpublished findings, which may 
decrease publication bias, was not performed. 
Conclusions drawn from this review should 
thus be considered provisional until the pro­
duction of quantitative summary estimates of 
RRs based on more thorough consideration of 
all available findings, with formal evaluation 
for   publication bias.
Evidence for plausible biologic mechanisms 
of health effects from dampness-related agents. 
Toxicologic evidence suggests plausible bio­
logic mechanisms for the respiratory health 
effects associated epidemiologically with damp­
ness or mold (WHO Europe 2009). In vitro 
and in vivo studies have demonstrated diverse 
inflammatory, cytotoxic, and immuno­
suppressive responses after exposure to the 
spores, metabolites, and components of specific 
microbial species found in damp buildings. 
Repeated immune activation and prolonged 
inflammation by microbiologic exposures 
may contribute to inflammation­related dis­
eases such as asthma. The immunosuppressive 
response demonstrated in animals exposed to 
fungal spores associated with damp buildings 
may explain a link to respiratory infections.
The wide variety of health effects associated 
with dampness and mold cannot be explained 
by a single mechanism. Epidemiologic evi­
dence suggests involvement of both allergic 
and nonallergic mechanisms, as both atopic 
and nonatopic individuals are susceptible to 
adverse effects of dampness or mold (e.g., 
Cox­Ganser et al. 2005; Dales et al. 2006; 
Douwes et al. 2006; Kuyucu et al. 2006). The 
inflammatory responses demonstrated in many 
microbiologic exposures include histamine 
release by non­immunoglobulin E–mediated 
mechanisms, providing plausible mechanisms 
for the occurrence of allergy­like symptoms in 
nonsensitized individuals. Increased human 
susceptibility to severe asthma exacerbation 
from fungal exposures has been demonstrated 
with genetic polymorphisms related to chi­
tinase, suggesting mechanisms involving fun­
gal chitin (Wu et al. 2010).
Some available evidence is consistent with 
involvement of fungal toxins in some health 
effects associated with damp environments, 
although this has been debated extensively 
in the literature (Bennett and Klich 2003; 
Jarvis and Miller 2005). Recently, animal 
models with curdlan (a specific triple­helical 
form of fungal glucan) and several toxic fun­
gal metabolites have demonstrated inflam­
matory, nonallergic respiratory health effects 
consistent with the epidemiology of damp­
ness (Miller et al. 2010; Rand et al. 2010). 
Observed synergistic interactions in toxico­
logic studies among microbial agents present 
in damp buildings, including specific fungi, 
actinomycetes, and amoebae (Penttinen et al. 
2006; Yli­Pirila et al. 2007) suggest that 
immunotoxic effects of fungal and bacterial 
strains typically found in damp buildings may 
be potentiated during joint exposures. Such 
potentiation could explain difficulties in iden­
tifying specific causal exposures for health 
effects in damp buildings.
Many limitations of culture­based micro­
bial assessments for investigating causes of 
dampness­related health effects have long 
been evident. Additional support for the need 
to investigate non­culture­based microbial 
assessment methods has been provided by the 
demonstration (Gorny et al. 2002) that fungi 
and actinomycetes can emit large numbers 
of airborne particles smaller than spores and 
not detectable by culture but with demon­
strated immunogenic properties. These find­
ings provide additional plausibility for health 
effects associated with microbial growth but 
not measurable with culture assays.
The hygiene hypothesis. As summarized 
in this review, indoor dampness or mold is 
consistently associated with increased respi­
ratory health risks, and microbial exposures 
have been suggested (but not proven) to play 
a causal role. On the other hand, an increas­
ing number of studies suggest that early­life 
microbiologic exposures to endotoxin or spe­
cific fungal agents may protect against atopy 
and allergic disease. This potentially protective 
effect is consistent with the “hygiene hypothe­
sis,” which postulates that growing up in a 
more microbiologically hygienic environment 
may increase the risk of developing respiratory 
allergies (e.g., Douwes et al. 2004, 2006; Liu 
and Leung 2006).
However, the evidence for protective effects 
of microbial exposures has not been consis­
tent, as increased health risks have been associ­
ated with some specific measured exposures 
(e.g., Bolte et al. 2003; Dharmage et al. 2001; 
Michel et al. 1996). Some of these inconsisten­
cies, found for endotoxin, (1→3)­β­d­glucans, 
and fungi, may be related to timing or dose 
of exposure, as has been recently hypothesized 
(Douwes et al. 2007), but evidence is still weak. 
For instance, Iossifova et al. (2007, 2009), in 
prospective data, identified nonmonotonic 
relationships between (1→3)­β­d­glucans in 
dust and recurrent wheeze, wheeze with atopy, 
and an index for future asthma: Risks increased 
at increasing low concentrations, reached a 
maximum at 60 µg/g dust, and then decreased 
at increasing high concentrations. Similar pat­
terns have also been observed with dust mite 
antigen (Tovey et al. 2008).
At present, modest exposure to some 
microbial exposures under certain circum­
stances appears to protect against allergies and 
allergic asthma but not wheeze; however, as 
indicated previously, the overall evidence is 
inconsistent. Damp or moldy buildings seem 
only to increase, not decrease, the develop­
ment of respiratory disease, both in allergic 
and nonallergic subjects including infants.
Suggested research. A focused research 
program in this area might include a) studies 
to identify and improve objective tools and 
metrics that, in assessing either dampness or 
specific related factors (microbiologic or non­
biologic), optimally predict disease; b) stud­
ies to characterize dose–response relations, to 
determine safe levels and identify age­or dose­
related protective effects; and c) strong stud­
ies (intervention or prospective) designed in 
the aggregate to document causality between 
dampness or mold and key health effects such 
as asthma or respiratory infections. Genetic 
epidemiology may enhance abilities to detect Health effects of dampness and mold
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causal exposures and identify mechanisms 
(Wu et al. 2010). Indoor occupational set­
tings and schools, with multiple advantages for 
study efficiency and logistics, have been under­
utilized. Good examples to follow include the 
strong disease prediction by an objective and 
easily interpreted tool, the electronic resistance­
type moisture meter (Williamson et al. 1997), 
and the well­designed and extremely effective 
remediation study by Kercsmar et al. (2006). 
Although future findings will improve health­
protective policies, health­protective actions 
need not await further etiologic research.
Conclusion
Based on the material reviewed here, there is 
sufficient evidence of an association between 
indoor dampness­related factors and a wide 
range of respiratory or allergic health effects 
(Table 3), including asthma development, 
asthma exacerbation, current asthma, ever 
asthma, dyspnea, wheeze, cough, respiratory 
infections, bronchitis, allergic rhinitis, eczema, 
and upper respiratory tract symptoms. There 
is suggestive evidence of associations with 
health effects for several non­culture­based 
measurements related to fungi and bacte­
ria in dust, although some of these associa­
tions seem equivocal. No evidence suggests 
protective effects of evident dampness and 
mold. Mechanisms seem likely to be both 
allergic and nonallergic. Available quantita­
tive meta­analyses have estimated consistently 
and significantly increased risks for multiple 
outcomes associated with dampness or mold, 
including OR ranges of 1.30–1.75.
Substantial increases in a number of impor­
tant respiratory health outcomes, including a 
50% increase in current asthma, are associated 
with dampness­related risk factors in residences 
(Fisk et al. 2007). These estimates, based on 
limited data, broad lumping of diverse risk 
factors, and multiple unverified assumptions, 
should be interpreted cautiously; however, they 
indicate that dampness­related risk factors may 
contribute substantially, but preventably, to the 
burden of respiratory disease.
In agreement with the IOM report (2004), 
we consider that there is not sufficient epide­
miologic evidence of a causal relationship for 
any of the reviewed health outcomes, although 
for asthma exacerbation in children we con­
sider the evidence strongly suggestive of cau­
sality by dampness­related agents. Although it 
is plausible that microbial exposures may play 
a causal role, specific causative agents have not 
been established. In fact, limited and inconsis­
tent evidence suggests that moderate exposures 
to certain microbial agents, especially at early 
ages, may prevent allergies and allergic asthma.
Based on available evidence, the presence 
of dampness, water damage, visible mold or 
mold odors or a history of water damage pro­
vides more reliable indicators of dampness­ or 
mold­related health risks than do current quan­
titative microbiologic assessments. As reduc­
tion of indoor dampness and mold is likely to 
have benefits for respiratory and allergic health 
of occupants, this level of knowledge should 
guide practical prevention and remedia  tion 
now. Still, available research does not yet indi­
cate the amount of water damage, mold, or 
mold odor meriting concern nor document 
the relative magnitude of health benefits from 
  different environmental remediations.
Although Williamson et al. (1997) pub­
lished findings of strong, dose­related asso­
ciations of asthma severity with systematic 
moisture measurements in walls 13 years ago, 
research use of quantified dampness metrics 
has not been reported since. Future research, 
generally, should develop objective metrics 
for dampness­related and microbial (or non­
microbial) risk factors that predict health 
effects. This will help in identifying specific 
causal dampness­related agents and character­
izing exposure–response relationships.
Challenges to progress include the wide 
variety of currently plausible micro  organisms 
(fungi, bacteria, amoebae/protozoans) and 
microbial components and products eligible 
to be causal factors; the potentially non­
monotonic effects of some of these compo­
nents (e.g., glucans and endotoxin); the 
potential synergistic actions of some organ­
isms, including actinomycetes and amoebae; 
the possible involvement of nonbiological, 
chemical agents released from damp indoor 
materials; and the modification of microbial 
effects by human age at exposure or by genetic 
or other host susceptibility factors. However, 
although their effectiveness may ultimately be 
improved, prevention and remediation actions 
to reduce indoor dampness are important and 
urgently needed in a large proportion of our 
building stock. These measures are likely to 
significantly reduce the current global burden 
of respiratory and   allergic disease.
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